These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18564271)

  • 1. Impaired glucose tolerance and the practical implications from a clinical perspective.
    Rahme K
    Int J Clin Pract; 2008 Jul; 62(7):988-9. PubMed ID: 18564271
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for the detection of impaired fasting glucose, impaired glucose tolerance and type 2 diabetes in welfare homes residents from south-eastern region of Poland.
    Grzywa M; Mazur A; Skrzypiec J
    Int J Clin Pract; 2011 Jul; 65(7):818-9. PubMed ID: 21676124
    [No Abstract]   [Full Text] [Related]  

  • 3. [Mass screening for reduced glucose tolerance].
    von Eyben FE
    Ugeskr Laeger; 2002 Sep; 164(36):4197-8; author reply 4198. PubMed ID: 12362840
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral glucose tolerance test in Italian overweight/obese children and adolescents results in a very high prevalence of impaired fasting glycaemia, but not of diabetes.
    Cambuli VM; Incani M; Pilia S; Congiu T; Cavallo MG; Cossu E; Sentinelli F; Mariotti S; Loche S; Baroni MG
    Diabetes Metab Res Rev; 2009 Sep; 25(6):528-34. PubMed ID: 19496065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of the determination of serum fructosamine in the screening of glucose intolerance].
    Ben Rayana MC; Aoun K; Achour A; Zouaghi H
    Ann Biol Clin (Paris); 1994; 52(5):389-90. PubMed ID: 7856941
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduced time points to calculate the composite index.
    DeFronzo RA; Matsuda M
    Diabetes Care; 2010 Jul; 33(7):e93. PubMed ID: 20587713
    [No Abstract]   [Full Text] [Related]  

  • 7. [Screening for diabetes: yes! but how?].
    Hauner H
    Dtsch Med Wochenschr; 2006 Oct; 131(40):2207. PubMed ID: 17021987
    [No Abstract]   [Full Text] [Related]  

  • 8. All pre-diabetes is not the same: metabolic and vascular risks of impaired fasting glucose at 100 versus 110 mg/dl: the Screening for Impaired Glucose Tolerance study 1 (SIGT 1).
    Phillips LS; Weintraub WS; Ziemer DC; Kolm P; Foster JK; Vaccarino V; Rhee MK; Budhwani RK; Caudle JM
    Diabetes Care; 2006 Jun; 29(6):1405-7. PubMed ID: 16732034
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucose intolerance and cardiometabolic risk in children exposed to maternal gestational diabetes mellitus in utero.
    Tam WH; Ma RC; Yang X; Ko GT; Tong PC; Cockram CS; Sahota DS; Rogers MS; Chan JC
    Pediatrics; 2008 Dec; 122(6):1229-34. PubMed ID: 19047239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finding undiagnosed type 2 diabetes: is it worth the effort?
    Engelgau MM; Narayan KM
    Eff Clin Pract; 2001; 4(6):281-3. PubMed ID: 11769302
    [No Abstract]   [Full Text] [Related]  

  • 11. High prevalence of neuropathy in patients with impaired 60-minute oral glucose tolerance test but normal fasting and 120-minute glucose levels.
    Sahin M; Karatas M; Sahin M; Ertugrul D; Kulaksizoğlu M; Dogruk A; Gokcel A; Tutuncu NB; Guvener ND; Kutlu M
    Minerva Endocrinol; 2008 Dec; 33(4):289-96. PubMed ID: 18923366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired fasting glucose and impaired glucose tolerance: implications for care.
    Nathan DM; Davidson MB; DeFronzo RA; Heine RJ; Henry RR; Pratley R; Zinman B;
    Diabetes Care; 2007 Mar; 30(3):753-9. PubMed ID: 17327355
    [No Abstract]   [Full Text] [Related]  

  • 13. The prevalence of impaired glucose metabolism in Hispanics with two or more risk factors for metabolic syndrome in the primary care setting.
    Neira CP; Hartig M; Cowan PA; Velasquez-Mieyer PA
    J Am Acad Nurse Pract; 2009 Mar; 21(3):173-8. PubMed ID: 19302694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fasting blood glucose and diagnosis of type 2 diabetes.
    Islam MS
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e26. PubMed ID: 21030102
    [No Abstract]   [Full Text] [Related]  

  • 15. The cost of screening for diabetes and intermediate hyperglycaemia.
    Colagiuri S
    Diabetes Res Clin Pract; 2012 Sep; 97(3):341-2. PubMed ID: 22682947
    [No Abstract]   [Full Text] [Related]  

  • 16. [Screening for type 2 diabetes and impaired glucose tolerance].
    Hirata A; Tominaga M
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():366-71. PubMed ID: 15779405
    [No Abstract]   [Full Text] [Related]  

  • 17. Impaired fasting glucose versus impaired glucose tolerance.
    Rajendran B
    J Assoc Physicians India; 2002 Apr; 50():614; author reply 614-5. PubMed ID: 12164431
    [No Abstract]   [Full Text] [Related]  

  • 18. Point-of-care testing as a tool for screening for diabetes and pre-diabetes.
    Rush E; Crook N; Simmons D
    Diabet Med; 2008 Sep; 25(9):1070-5. PubMed ID: 19183312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for NIDDM. Opportunities for detection, treatment, and prevention.
    Knowler WC
    Diabetes Care; 1994 May; 17(5):445-50. PubMed ID: 8062614
    [No Abstract]   [Full Text] [Related]  

  • 20. [Oral glucose tolerance test. Not useful in screening of type 2 diabetes].
    Hermanides J; Hoekstra JB
    Ned Tijdschr Geneeskd; 2009 Apr; 153(16):743. PubMed ID: 19469143
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.